Acropolis Investment Management buys $1,131,358 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Acropolis Investment Management scooped up 280 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 5, 2016. The investment management firm now holds a total of 14,585 shares of Gilead Sciences which is valued at $1,131,358.Gilead Sciences makes up approximately 0.21% of Acropolis Investment Management’s portfolio.

Other Hedge Funds, Including , North Star Asset Management Inc sold out all of its stake in GILD during the most recent quarter. The investment firm sold 3,651 shares of GILD which is valued $283,208. Kempner Capital Management added GILD to its portfolio by purchasing 10,810 company shares during the most recent quarter which is valued at $838,532. Gilead Sciences makes up approx 0.58% of Kempner Capital Management’s portfolio.Washington Trust Bank reduced its stake in GILD by selling 2,270 shares or 37.2% in the most recent quarter. The Hedge Fund company now holds 3,832 shares of GILD which is valued at $297,248. Gilead Sciences makes up approx 0.07% of Washington Trust Bank’s portfolio.Bath Savings Trust Co reduced its stake in GILD by selling 980 shares or 2.51% in the most recent quarter. The Hedge Fund company now holds 38,125 shares of GILD which is valued at $2,957,356. Gilead Sciences makes up approx 0.93% of Bath Savings Trust Co’s portfolio.Lau Associates reduced its stake in GILD by selling 700 shares or 2.45% in the most recent quarter. The Hedge Fund company now holds 27,900 shares of GILD which is valued at $2,164,203. Gilead Sciences makes up approx 2.21% of Lau Associates’s portfolio.

Gilead Sciences closed down -0.79 points or -1.01% at $77.24 with 82,19,372 shares getting traded on Tuesday. Post opening the session at $77.6, the shares hit an intraday low of $77.12 and an intraday high of $78.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Oct 3, 2016 to “Outperform” and Lowered the Price Target to $ 95 from a previous price target of $105 .Shares were Downgraded by Leerink Partners on Sep 27, 2016 to ” Mkt Perform” and Lowered the Price Target to $ 94 from a previous price target of $112 .Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.